Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

This study tests whether combining cadonilimab (an immunotherapy drug) with an oral chemotherapy pill (S-1 or capecitabine) can help people with locally advanced pancreatic cancer that has not responded well to their first treatment. Pancreatic cancer is notoriously difficult to treat, and researchers are looking for new second-line options for patients who have already tried standard therapy. **You may be eligible if...** - You are 18 to 80 years old - You have confirmed pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) - Your cancer is locally advanced (not yet spread to distant organs) and has already been treated with at least one standard treatment - You have at least one measurable tumor on a scan - You are in reasonably good health (ECOG 0-1) with expected survival over 3 months - Your organ function is adequate **You may NOT be eligible if...** - You have another active cancer (other than certain skin cancers that have been treated) - You are currently in another clinical trial - You have active autoimmune disease - You have had an organ or stem cell transplant - You have a known allergy to cadonilimab, S-1, or capecitabine Talk to your doctor to see if this trial is right for you.